Facebook Twitter LinkedIn

Mr. Joseph M. Fernández

Chairman

Co-founder of Invitrogen, Inc., (Currently Life Technologies); founder and CEO/Chairman of Active Motif Inc., which specializes in novel tools and platform technologies for genomics-driven cell biology and epigenetic pathway elucidation.

Other mandates

  • Chairman of the Board of Directors of Active Motif Chromeon GmbH, Tegernheim, Germany
  • Member of the Board of Directors of Expedeon Inc., Cambridge, UK
  • Member of the Board of Directors of Hiram College, Hiram, Ohio, USA
  • Member of the Board of Directors of protein fluidics, Santa Clara, CA, USA
  • Member of the Board of Directors of Delegate Advisors, San Francisco, CA, USA

Pilar de la Huerta

Member of the Supervisory Board

Pilar de la Huerta has accumulated an extensive experience in the pharma and biotech sector over the last 20 years. She joined Genetrix group as a CEO in 2010, moving to SYGNIS after the merger done between Xpol, Genetrix subsidiary, and SYGNIS AG in october 2012. From 2006 to 2010, she was a strategic consultant within several companies, such as Viamed Salud Group, where she was responsible for R&D and New Business and was appointed CEO of the two most innovative companies within the Group: Araclon Biotech, SL. and Viamed Technology Investments. Before that, she was CEO at Neuropharma (Noscira, Zeltia Group) and assumed various responsibilities within the Zeltia Group, (the biggest quoted biotech holding in Spain).

Pilar holds a Master Degree in Business and Administration by the UCM and has completed the IESE’s Advanced Management Program (AMP) and Program for Management Development (PMD) courses in the Navarra University.

Other mandates

  • Member of the Supervisory Board and CEO of ADL Biopharma, Madrid, Spain
  • Member of the Supervisory Board of Epidesease SL, Madrid, Spain

Peter Llewellyn-Davies

Member of the Supervisory Board

Peter Llewellyn-Davies is a strategic CEO/CFO with an over 25 year track record in financing activities, international M&A deals, company turnarounds, licensing transactions and with particular experience in chemical and healthcare industries. Currently Peter supports small and medium sized companies with his consulting company Accellerate Partners, targeting in particular enterprises who require the support of a strategically orientated CFO but do not need a full time executive to cover this role. Peter is a non-executive Director and chair of the Audit Committee of Shield Therapeutics plc, who in 2016 completed an AIM listing in London.

Peter was CFO/CBO of Medigene AG between 2012 and 2016 and supported the turnaround process by creating an equity story, outlicensing marketed and legacy products and enhancing shareholder value with a new large international investor base.

Prior to that he was CFO of Wilex AG, having orchestrated their IPO in 2006 to fund a later stage pipeline, setting up investor and public relations and concluding subsequent partnering deals and acquisitions. Prior to this, he was Executive Director of Müller Dairy (UK) Ltd and Executive Director Finance at Süd-Chemie AG. Peter read business management, banking, marketing and controlling in London, St. Gallen and Munich, and has a certificate in business studies from the University of London.

Other mandates

  • CEO and CFO of APEIRON Biologics AG, Vienna, Austria
  • Member of the Supervisory Board and Chairman of the Audit Committee of Shield Therapeutics plc, London, UK

Mr. Tim McCarthy

Member of the Supervisory Board

Tim has a 35 year international business career in high growth Healthcare, Biotech and Technology companies and is currently Chairman and Non Executive Director for a number of companies, including Immupharma Plc, Incanthera, Expedeon Holdings and Harvard Healthcare. He is a former CEO and Finance Director of public and private companies, including Alizyme plc, Peptide Therapeutics Group plc. He has co-founded a number of healthcare and biotechnology companies, raising substantial amounts of equity capital and also advised and/or worked at Board level, for a diverse range of companies internationally, in areas such as business strategy, fund raising, mergers & acquisitions, due diligence and licensing. A Fellow of the Association of Chartered Certified Accountants, he also has an MBA from Cranfield School of Management.

Other mandates

  • Chairman of the Board of Directors of ImmuPharma plc, London, UK
  • Chairman of the Board of Directors of ARK Analytics Solutions Ltd, Cambridge, UK
  • Member of the Board of Directors of Spear Therapeutics Ltd, Manchester, UK
  • Chairman of the Board of Directors of Dropped Ltd, Cambridge, UK
  • Chairman of the Board of Directors of Incanthera Ltd, Manchester, UK
  • Chairman of the Board of Directors of Harvard Healthcare Ltd, Liverpool, UK
  • Member of the Board of Directors of Wise old owl Ltd, Cambridge, UK
  • Member of the Board of Directors of Frangipani Dreams Ltd, Cambridge, UK

Dr. Trevor Jarman

Member of the Supervisory Board

Dr Trevor Jarman is an innovative biochemist who has been involved in the founding and development of various businesses in the life sciences and healthcare sectors. He was a co-founder and Business Development Director of Alizyme plc, which was a developer of pharmaceuticals. He has been a member of the Board of Directors of Expedeon Holdings Ltd since its founding in 2003. He holds a Bachelor of Science (BSc) and doctorate in Biochemistry from the University of Hull, and has worked in the Faculty of Chemistry at Imperial College, London.

Chief Executive Director of Natures Remedies Ltd., Cambridge, U.K.

Other mandates

  • Member of the Board of Directors of Expedeon Ltd, Cambridge, UK
  • Chairman of The Board of Directors of Persavita Ltd, Cambridge, UK
  • Chief Executive Director of Natures Remedies Ltd, Cambridge, UK
  • Member of the Board of Directors of Cambridge Cell Networks Ltd, Cambridge, UK
  • Member of the Board of Directors of Swangap Flat Management Ltd, Cambridge, UK
  • Member of the Board of Directors of Protus Ltd, Cambridge, UK